A real-world prospective study of nivolumab (NIVO) in patients (pts) with pretreated advanced non-small cell lung cancer (aNSCLC) in Greece and Cyprus – Interim analysis results of LUCENCE study

This is an ongoing study with a planned size of 200 adult pts with squamous or non-squamous cell carcinoma (NSQ), initiated on NIVO as per label. Data are collected at enrollment and routine clinic visits up to 60 months post-baseline. Herein, we present 12-month outcomes of the first 100 eligible pts. Pts were enrolled from Nov-2020 to Oct-2021 by 14 oncology clinics in Greece. 82% were male, 66% had NSQ and 90% started NIVO as 2LT. Median age was 70.0 years, 96% had ECOG PS scores of 0-1, and 9%/1%/90% had Stage IIIB/IIIC/IV. Among tested pts, all were ALK wild type (50/50), 98% were EGFR wild type (53/54), and 41% (26/64) had tumor PD-L1≥1% (PD-L1≥50% in 27%). Median duration of prior therapy for aNSCLC was 3.0 months; chemotherapy (100%), targeted therapy (10%) and immunotherapy (4%). Median follow-up (FU) time until the IA data cutoff was 9.2 months. At 12 months, rates of OS and PFS were 80% and 44% respectively, 58% of pts had discontinued NIVO (57% of whom had started next line treatment), and 56% had been withdrawn from the study. NIVO-related adverse event rate was 20% (4% serious; 9% immune-related). In LUCENCE study, NIVO demonstrates effectiveness in the 2L+ setting for aNSCLC. Mature final data from the full cohort and longer FU are needed to confirm our findings. <fig><object-id>erj;64/suppl_68/PA5122/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>